Voyager Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to leveraging human genetics to develop neurogenetic medicines and gene therapies for neurological diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Voyager utilizes its proprietary TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform to engineer novel adeno-associated virus (AAV) capsids capable of crossing the blood-brain barrier with enhanced central nervous system tropism and reduced off-target organ distribution. The company is advancing a proprietary and partnered pipeline targeting Alzheimer's disease (including VY7523, an anti-tau monoclonal antibody in Phase 1, and VY1706, a tau-silencing AAV gene therapy entering Phase 1), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Friedreich's ataxia (NBIB-223, partnered with Neurocrine Biosciences). In November 2026, Voyager disclosed in its Q3 Form 10-Q an implemented workforce reduction and $1.4 million in restructuring charges to reduce operating expenditures and extend cash runway into Q2 2028.
Phase 1 MAD tau PET imaging efficacy readout for anti-tau antibody VY7523 in Alzheimer's disease
First patient dosing in Phase 1 trial of tau-silencing gene therapy VY1706 in early Alzheimer's disease
Voyager Therapeutics disclosed in its Q3 2026 Form 10-Q filing on November 5 and BioSpace Layoff Tracker report on November 6 that it executed an internal reduction in force during the third quarter to curb operating expenses and align capital with strategic priorities. The company incurred .4 million in severance and employee termination benefits across R&D and G&A, while extending its 32 million cash runway into Q2 2028 as it advances its TRACER AAV capsid neurodegenerative programs, including Phase 1 clinical-stage anti-tau antibody VY7523.
Voyager Therapeutics disclosed an internal reduction in force and $1.4 million in Q3 restructuring charges, extending its $132M cash runway into Q2 2028 while advancing Phase 1 anti-tau programs.
Chief Executive Officer
President
Chief Financial Officer
Chief Scientific Officer